BTK Inhibitor Evobrutinib Fails to Meet Primary End Points in Phase 3 EVOLUTION Trials
Results showed that evobrutinib did not produce a more superior reduction in annualized relapse rates than teriflunomide, a previously approved disease-modifying agent.
Noord Holland National Harbor United States Merck Kgaa Darmstadt Consortium Of Multiple Sclerosis Centers Merck Kgaa
Source: ajmc.com